Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Editorial Commentaries

Cerebrovascular Challenges in Diabetic Patients

The Pressure Is on to Maintain Perfusion

Jill N. Barnes, Michael J. Joyner
Download PDF
https://doi.org/10.1161/HYPERTENSIONAHA.110.168070
Hypertension. 2011;57:674-675
Originally published March 16, 2011
Jill N. Barnes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Joyner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
Loading

See related article, pp 738–745

In this edition of Hypertension, Kim et al1 report that cerebral perfusion is differentially effected by pharmacological blood pressure treatment in hypertensive patients, uncomplicated type II diabetics, and type II diabetics with microvascular complications. Specifically, they reported a progressive decrease in cerebral blood flow after 6 months of antihypertensive medication in diabetics with microvascular complications, whereas cerebral blood flow in hypertensive or uncomplicated diabetics was only marginally reduced by treatment. In addition, the diabetics with microvascular complications demonstrated a blunted cerebral responsiveness to CO2 but similar middle cerebral artery blood velocity compared with hypertensives and uncomplicated diabetics before treatment for their hypertension. However, it is unknown whether the blunted cerebral vasodilator responses at baseline were caused by the same mechanisms that reduced middle cerebral artery blood velocity after blood pressure treatment.

When the findings of Kim et al1 are viewed in an epidemiological context, it is interesting to note that, in middle-aged and older humans, obesity, diabetes mellitus, hypertension, and physical inactivity frequently coexist in the same patients. All of these conditions are associated with vascular dysfunction in both large conduit vessels and the microcirculation, and all have emerged as major risk factors for mild cognitive impairment and Alzheimer disease.2,3 Furthermore, reduced brain volume associated with any of these conditions may mediate the decline in cognitive function.4 By contrast, recent evidence suggests that physical activity might be protective against mild cognitive impairment and Alzheimer disease,5,6 although the mechanisms are unknown. Extrapolation of the data from Kim et al1 suggests a potential physiological link between so-called vascular risk factors and cognitive decline in patients with long-standing diabetes mellitus and hypertension.

In this context, a few questions come to mind. First, because diabetes mellitus is associated with macrovascular and microvascular dysfunction, is it possible that high resting blood pressure in complicated diabetes mellitus is a compensatory mechanism to maintain adequate cerebral perfusion? This concept has emerged for other critical organs like the heart and kidneys, but does it also operate in the brain? Second, does reduced cerebral vasodilator responsiveness to CO2 mean that cerebral vasodilator responses to increased neural activity will also be blunted? Third, is the reduced cerebral vasodilator response attributed to the effects of hyperglycemia, per se, or does it reflect a more long-term maladaptive response to diabetes mellitus? Fourth, will blunted cerebral vasodilator responses to increased neural activity eventually cause brain atrophy? Finally, will this lead to a vicious cycle of reduced cerebral perfusion, brain atrophy, and lower metabolic demand? In addition, whereas increases in perfusion pressure in the short run might maintain cerebral blood flow, over time they might evoke so-called end organ damage and further deteriorate the inherent ability of the cerebral microvessels to dilate in response to chemical, autoregulatory, or metabolic stimuli. Thus, how do we maintain blood flow in the normal range and enhance local vasodilator responses in the absence of a rise in blood pressure?

In other vascular beds, endurance exercise interventions consistently demonstrate improved macrovascular and/or microvascular function in middle-aged and older adults.7,8 These findings clearly provide a rationale for examining the effect of endurance exercise training on cerebral perfusion, particularly in diabetics and/or hypertensive individuals with microvascular complications. The diabetic patients would be further served by the powerful antidiabetic effects of exercise.9 If endurance exercise training improves microvascular function in middle-aged and older adults, the effect is likely systemic and will, therefore, improve cerebral perfusion. Maintaining or increasing cerebral perfusion (in addition to cerebral responsiveness to CO2 and autoregulatory mechanisms) is also of critical importance in aging humans who are at risk for both cognitive decline and vascular dysfunction. Cognitive function is closely associated with cerebral blood flow and brain atrophy, and a reduction in either may precipitate the age-related decline in cognitive function.10 The association between brain volume and blood flow is particularly striking in individuals with either mild cognitive impairment or mild Alzheimer disease.11 In this context, physical activity has been shown to prevent the age-related decline in cognitive function and may be associated with a greater brain volume. Although Kim et al1 showed that cognitive function did not change over the 6 months of treatment, longer-term follow-up may be necessary for interventional studies.

In conclusion, the epidemiological evidence clearly shows reduced mortality and incidence of cardiovascular events with blood pressure–lowering medications. However, it is unclear what the impact of this treatment has on long-term cognitive function and how it is physiologically linked to changes in brain blood flow. Finally, will exercise training in fact triple the reward in hypertensive diabetics by improving their blood pressure, improving glycemic control, and improving brain blood flow?

Disclosures

None.

Footnotes

  • The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.

  • © 2011 American Heart Association, Inc.

References

  1. 1.↵
    1. Kim Y-S,
    2. Davis SCAT,
    3. Truijen J,
    4. Stok WJ,
    5. Secher NH,
    6. van Lieshout JJ
    . Intensive blood pressure control affects cerebral blood flow in type 2 diabetes mellitus patients. Hypertension. 2011:57:738–745.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Kivipelto M,
    2. Helkala EL,
    3. Hanninen T,
    4. Laakso MP,
    5. Hallikainen M,
    6. Alhainen K,
    7. Soininen H,
    8. Tuomilehto J,
    9. Nissinen A
    . Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology. 2001;56:1683–1689.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Roberts RO,
    2. Geda YE,
    3. Knopman DS,
    4. Christianson TJ,
    5. Pankratz VS,
    6. Boeve BF,
    7. Vella A,
    8. Rocca WA,
    9. Petersen RC
    . Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol. 2008;65:1066–1073.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Jack CR Jr.,
    2. Shiung MM,
    3. Gunter JL,
    4. O'Brien PC,
    5. Weigand SD,
    6. Knopman DS,
    7. Boeve BF,
    8. Ivnik RJ,
    9. Smith GE,
    10. Cha RH,
    11. Tangalos EG,
    12. Petersen RC
    . Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004;62:591–600.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Ainslie PN,
    2. Cotter JD,
    3. George KP,
    4. Lucas S,
    5. Murrell C,
    6. Shave R,
    7. Thomas KN,
    8. Williams MJ,
    9. Atkinson G
    . Elevation in cerebral blood flow velocity with aerobic fitness throughout healthy human ageing. J Physiol. 2008;586:4005–4010.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Lautenschlager NT,
    2. Cox KL,
    3. Flicker L,
    4. Foster JK,
    5. van Bockxmeer FM,
    6. Xiao J,
    7. Greenop KR,
    8. Almeida OP
    . Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA. 2008;300:1027–1037.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Black MA,
    2. Green DJ,
    3. Cable NT
    . Exercise prevents age-related decline in nitric-oxide-mediated vasodilator function in cutaneous microvessels. J Physiol. 2008;586:3511–3524.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. DeSouza CA,
    2. Shapiro LF,
    3. Clevenger CM,
    4. Dinenno FA,
    5. Monahan KD,
    6. Tanaka H,
    7. Seals DR
    . Regular aerobic exercise prevents and restores age-related declines in endothelium-dependent vasodilation in healthy men. Circulation. 2000;102:1351–1357.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Stewart KJ
    . Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health. JAMA. 2002;288:1622–1631.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Poels MM,
    2. Ikram MA,
    3. Vernooij MW,
    4. Krestin GP,
    5. Hofman A,
    6. Niessen WJ,
    7. van der Lugt A,
    8. Breteler MM
    . Total cerebral blood flow in relation to cognitive function: the Rotterdam Scan Study. J Cereb Blood Flow Metab. 2008;28:1652–1655.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Luckhaus C,
    2. Cohnen M,
    3. Fluss MO,
    4. Janner M,
    5. Grass-Kapanke B,
    6. Teipel SJ,
    7. Grothe M,
    8. Hampel H,
    9. Peters O,
    10. Kornhuber J,
    11. Maier W,
    12. Supprian T,
    13. Gaebel W,
    14. Modder U,
    15. Wittsack HJ
    . The relation of regional cerebral perfusion and atrophy in mild cognitive impairment (MCI) and early Alzheimer's dementia. Psychiatry Res. 2010;183:44–51.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
April 2011, Volume 57, Issue 4
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Cerebrovascular Challenges in Diabetic Patients
    Jill N. Barnes and Michael J. Joyner
    Hypertension. 2011;57:674-675, originally published March 16, 2011
    https://doi.org/10.1161/HYPERTENSIONAHA.110.168070

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Cerebrovascular Challenges in Diabetic Patients
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Cerebrovascular Challenges in Diabetic Patients
    Jill N. Barnes and Michael J. Joyner
    Hypertension. 2011;57:674-675, originally published March 16, 2011
    https://doi.org/10.1161/HYPERTENSIONAHA.110.168070
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Heart Failure and Cardiac Disease
    • Metabolic Syndrome

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured